Immunology 2020 is immensely pleased to invite all the researchers for our upcoming “13th Global Summit on Immunology And Cell Biology” which is going to be held during October 26-27, 2020 at Amsterdam, Netherlands with a theme “Igniting new Achievements, Advancements And new Discoveries In the field of Immunology”

Immunology 2020 gives a complete overview on complete overview on Immunology, Cancer Immunology and Immunotherapy, Transplantation Immunology, Immunogenetics, Viral Immunology, Parasite Immunology, Pediatrics Immunology, Cellular and Molecular Immunology, ImmunoInformatics.

Immunology Conferences will empower us to continue plunging further into both the examination of Immunology & Cell Biology change and the business necessities for associations. Immunology2020 is the platform where you can meet scientists, authorities and CROs from around the world.

CONFERENCE OPPORTUNITIES:

• Keynote Presentations
• Speaker Presentations
• Yong Researcher Forum (YRF)
• Poster Presentation
• Video Presentation
• E-Poster
• Work Shop
• Exhibition
• Symposium
• Collaboration
• Sponsorship

Market Analysis:

The global immunology market size was valued at USD 77,365.4 Million in 2018 and is projected to reach USD 143,833.2 Million by 2026, exhibiting a CAGR of 8.1% in the forecast period.

Existing market players operating in the global immunology market are focusing on constant innovations and up-gradation of their product portfolio with new and efficient product offerings for better treatment outcomes for the patients. One of the primary reasons for the growth of the global market is the increasing incidence of immunological and autoimmune diseases. Rise in awareness regarding immunological diseases in both developing and developed nations, and the higher prevalence of immunological disorders due to environmental factors, thus propelling the of the global immunology market growth. This coupled with, increasing investments by major players in research and development activities are also boosting the growth of the market globally.

The change in the immunology market share is also primarily driven by a greater focus towards the R&D initiatives due to recent regulatory approvals, increasing trends of patent expiry and the subsequent emergence of comparatively cheaper Biosimilars. Some of the other factors which are also contributing to the growth of the market are the increase in the efficiency of the immunology drugs leading to better patient outcomes and improved quality of life.

The introduction of new and sophisticated targeted therapies such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG is expected to drive the growth of the immunology market in developed as well as emerging countries, during the forecast period 2019-2026."Increasing adoption of monoclonal antibody (mAb), combined with the increasing prevalence of immunological diseases is driving the growth of the global market".

Increasing adoption and demand for monoclonal antibody (mAb), which is the drug class of a number of immunology drugs and has a number of associated advantages such as its status as a high specific therapy, is one of the most prominent driving factors for the growth of the global immunology industry in 2018. Increasing R&D initiatives in the monoclonal antibody segment and a large number of drugs under the segment is also driving the growth in the monoclonal antibody (mAb) segment.

The immunosuppressant segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the anticipated increase in the revenue under this drug class, with the interleukin inhibitors becoming more prominent in the immunology market trend. Currently, there is increasing adoption of the immunosuppressants in the markets in the developing nations due to its higher achievement in terms of the efficient treatment leading to improved patient outcomes, and this is expected to contribute to the growth of the market at higher CAGRs during the forecast period.

Regional Analysis

"Growing Prevalence and Awareness of Autoimmune and Immunological Disorders and Increasing Adoption of Immunology Drugs Expected to Result in the Highest CAGR in the Asia Pacific"

North America generated revenue of US$ 41,622.5 Mn in 2018 and is anticipated to account for a dominant share in the global market during the forecast period. The immunology market growth witnessed in the region is likely to be driven by the increasing adoption of advanced immunology drugs and rising prevalence of autoimmune and immunological disorders.

This is especially applicable in instances where there is a steady escalation of the symptoms and the disease progresses due to lack of efficient treatment. In developed countries, the adoption of advanced immunology drugs such as immunosuppressants is increasing along with the existing drug classes of monoclonal antibody (mAb) and polyclonal antibody (pAb) amongst others .

For any further details, benefits, submission of research papers, participation, please contact:

Andrew George
Program Manager | Immunology 2020
Whatsapp: 44-146-931-0004
Email: Immunology@europeconferences.com | contact@europemeet.com
Web: https://immunology.conferenceseries.com/